top of page


Alderley Park, Cheshire, UK - February 21, 2024

Maxwellia is delighted to announce the launch of LoviTest™, a convenient at-home STI testing service for chlamydia and gonorrhoea. LoviTest marks the latest addition to Maxwellia's direct-to-consumer (D2C) sexual health offering,, complementing their over-the-counter contraception brands Lovima® and LoviOne®.


LoviTest™ is specifically designed for the detection of genital Chlamydia and Gonorrhoea infections, offering users the convenience and discretion of at-home testing. The kit provides options for either a urine sample or a vaginal swab, ensuring a hassle-free sample collection process, along with free return postage, and results within 48-hours of the sample being received.


Recent statistics highlight the need for greater awareness and access to STI testing solutions. In 2022 alone, there were 392,4531 diagnoses of new STIs in England, representing a significant increase of 23.8% compared to the previous year1. Specifically, chlamydia diagnoses increased by 24.3%, reaching 199,233 cases in 20221, while gonorrhoea diagnoses surged by 50.3%, totalling 82,592 cases1.

LoviTest Maxwellia Website Image.jpg

Speaking about the launch, Maxwellia's CEO Anna Maxwell stated, "With the alarming rise in STI diagnoses, there's an evident demand for accessible and confidential testing solutions. LoviTest™ empowers individuals to take charge of their sexual health from the comfort and privacy of their own homes. We are committed to providing innovative and effective solutions to support overall sexual health and wellbeing."


Maxwellia have partnered with a fellow Catapult Ventures portfolio business, Biofortuna, to deliver the tests and sample analysis. Deeside based Biofortuna is a specialist outsourcing partner for a range of genomic and testing services. Speaking of the partnership, Biofortuna’s CEO Nick Ash commented “We’re delighted to be working with Maxwellia on their new STI testing brand, LoviTest™. By combining our expertise and infrastructure with Maxwellia’s existing sexual health D2C platform, we hope to increase access to STI testing and help to prevent the onward transmission of infections.”


LoviTest™ is now available for purchase on, further expanding Maxwellia's commitment to empowering individuals to make informed decisions about their sexual health.







bottom of page